相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes-2022
DIABETES CARE (2022)
Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis
Takayuki Yamada et al.
CARDIOVASCULAR DIABETOLOGY (2021)
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial
David Z. I. Cherney et al.
DIABETOLOGIA (2021)
Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
Jae Hyun Bae et al.
ENDOCRINOLOGY AND METABOLISM (2021)
Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial
M. Angelyn Bethel et al.
DIABETES CARE (2020)
Prevalence and risk factors of chronic kidney disease and diabetic kidney disease in a central Chinese urban population: a cross-sectional survey
Jia-Yu Duan et al.
BMC NEPHROLOGY (2020)
Prevalence and Risk Factors of Chronic Kidney Disease among Type 2 Diabetes Patients: A Cross-Sectional Study in Primary Care Practice
Janjira Jitraknatee et al.
SCIENTIFIC REPORTS (2020)
Alogliptin after acute coronary syndrome in patients with type 2 diabetes: a renal function stratified analysis of the EXAMINE trial
Joao Pedro Ferreira et al.
BMC MEDICINE (2020)
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study
Shun Kohsaka et al.
Lancet Diabetes & Endocrinology (2020)
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J. L. Heerspink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Limited Knowledge of Chronic Kidney Disease among Type 2 Diabetes Mellitus Patients in India
Salman Hussain et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2019)
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Mansoor Husain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis
Yue Fei et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition
Pouya Saeedi et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2019)
Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA
Darren K. McGuire et al.
CIRCULATION (2019)
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk The CARMELINA Randomized Clinical Trial
Julio Rosenstock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data From the CANVAS Program
Brendon L. Neuen et al.
CIRCULATION (2018)
CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease
Hans-Joachim Anders et al.
NATURE REVIEWS NEPHROLOGY (2018)
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
Christoph Wanner et al.
CIRCULATION (2018)
Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease Results From the LEADER Trial
Johannes F. E. Mann et al.
CIRCULATION (2018)
Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects
Hiddo J. L. Heerspink et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Liraglutide and Renal Outcomes in Type 2 Diabetes
Johannes F. E. Mann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Proposal of a Novel Mechanism of Action
Milton Packer et al.
JAMA CARDIOLOGY (2017)
Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS
Jan H. Cornel et al.
DIABETES CARE (2016)
SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
Naveed Sattar et al.
DIABETOLOGIA (2016)
Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014
Maryam Afkarian et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
Heidi Storgaard et al.
PLOS ONE (2016)
Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment-patterns-NHANES 2007-2012
Bingcao Wu et al.
BMJ OPEN DIABETES RESEARCH & CARE (2016)
Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class?
Konstantinos P. Imprialos et al.
JOURNAL OF HYPERTENSION (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Diabetic kidney disease
Merlin C. Thomas et al.
NATURE REVIEWS DISEASE PRIMERS (2015)
Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial
Jacob A. Udell et al.
DIABETES CARE (2015)
Prevalence of complications among Chinese diabetic patients in urban primary care clinics: a cross-sectional study
Kenny Kung et al.
BMC FAMILY PRACTICE (2014)
Kidney Disease and Increased Mortality Risk in Type 2 Diabetes
Maryam Afkarian et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2013)
Prevalence, screening and treatment of chronic kidney disease in people with type 2 diabetes in France: The ENTRED surveys (2001 and 2007)
G. F. A. Assogba et al.
DIABETES & METABOLISM (2012)
Risk factors for renal dysfunction in type 2 diabetes - UK prospective diabetes study 74
Ravi Retnakaran et al.
DIABETES (2006)
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
BM Brenner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
EJ Lewis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
